Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.21% | 5.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.91% | 20.09% | |||
| Operating Income | 17.91% | -20.09% | |||
| Income Before Tax | 18.86% | -23.76% | |||
| Income Tax Expenses | -100.00% | -57.60% | |||
| Earnings from Continuing Operations | 18.92% | -23.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.92% | -23.59% | |||
| EBIT | 17.91% | -20.09% | |||
| EBITDA | 17.94% | -20.15% | |||
| EPS Basic | 19.62% | -23.13% | |||
| Normalized Basic EPS | 19.55% | -23.27% | |||
| EPS Diluted | 19.62% | -23.13% | |||
| Normalized Diluted EPS | 19.55% | -23.27% | |||
| Average Basic Shares Outstanding | 0.88% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.88% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
